SG11201809387QA - Compositions and methods related to hiv-1 immunogens - Google Patents

Compositions and methods related to hiv-1 immunogens

Info

Publication number
SG11201809387QA
SG11201809387QA SG11201809387QA SG11201809387QA SG11201809387QA SG 11201809387Q A SG11201809387Q A SG 11201809387QA SG 11201809387Q A SG11201809387Q A SG 11201809387QA SG 11201809387Q A SG11201809387Q A SG 11201809387QA SG 11201809387Q A SG11201809387Q A SG 11201809387QA
Authority
SG
Singapore
Prior art keywords
hiv
international
immunogens
jolla
san diego
Prior art date
Application number
SG11201809387QA
Inventor
Leopold Kong
Ian Wilson
Val Natalia De
Andrew Ward
Dennis Burton
Linling He
Jiang Zhu
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of SG11201809387QA publication Critical patent/SG11201809387QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Nanotechnology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 11111111111111111111111111111111111111111111111111111111111111111111111111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2017/192434 Al 09 November 2017 (09.11.2017) WIP0 I PCT (51) International Patent Classification: San Diego, CA 92109 (US). BURTON, Dennis; 6044 C07K 14/005 (2006.01) Cl 2N 7/00 (2006.01) Beaumont Avenue, La Jolla, CA 92037 (US). HE, Lin- A61K 45/06 (2006.01) ling; 4267 Robins Street, San Diego, CA 92122 (US). ZHU, (21) International Application Number: Jiang; 4267 Robins Street, San Diego, CA 92122 (US). PCT/US2017/030375 (74) Agent: FITTING, Thomas et al.; The Scripps Research In- (22) International Filing Date: stitute, 10550 North Torrey Pines Road, TPC-8, La Jolla, 01 May 2017 (01.05.2017) CA 92037 (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (26) Publication Language: English AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (30) Priority Data: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, 62/330,604 02 May 2016 (02.05.2016) US DZ, HR, EC, EE, EG, ES, Fk GB, GD, GE, GH, GM, GT, HN, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, (71) Applicant: THE SCRIPPS RESEARCH INSTITUTE KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, [US/US]; 10550 North Torrey Pines Road, La Jolla, CA MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, 92037 (US). PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (72) Inventors: KONG, Leopold; 4920 Battery Lane, #3, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Bethesda, MD 20814 (US). WILSON, Ian, A.; 1025 — Newkirk Drive, La Jolla, CA 92037 (US). DE VAL, Na- (84) Designated States (unless otherwise indicated, for every talia; 4860 Clairemont Mesa Blvd., #4, San Diego, CA kind of regional protection available): ARIPO (BW, GH, 92117 (US). WARD, Andrew, B.; 4965 Academy Street, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, = = _ _ (54) Title: COMPOSITIONS AND METHODS RELATED TO HIV-1 IMMUNOGENS _ - T . . _ = HR ty = _ i 1 04.... _ daavaga We — = = b 041 = \"12° ii ilit\" Rational Waldo of1191 Pktwrdinua RRI = 3.S T8Q50 A.53131 = = C = = - SIM 1 LC 1 , 11 = IOC- , , pace # Enertni Design li t ll :VI' Sta# 3 7=tg ai \"'\" 4 4 POI 3 P V IV /mat of al desi t*, ranki ns na g 71' en 71' ei cn FIG. 1 ,-1 -- -- t .., (57) : The present invention provides HiV-1 vaccine immunogens. Some of the immunogens contain a soluble gp140-derived - protein that harbors a modified N- terminus of the HR1 region in gp41. Some of the immunogens contain an HIV-1 Env- derived trimer 0 protein that is presented on 8 nanoparticle platform. The invention also provides methods of using the HIV-1 vaccine immunogens for ei eliciting an immune response or treating HIV infections. [Continued on next page] WO 2017/192434 Al IMEDIMOM0101011MMEMOMOMMEHHOOMMEM1011 UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
SG11201809387QA 2016-05-02 2017-05-01 Compositions and methods related to hiv-1 immunogens SG11201809387QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662330604P 2016-05-02 2016-05-02
PCT/US2017/030375 WO2017192434A1 (en) 2016-05-02 2017-05-01 Compositions and methods related to hiv-1 immunogens

Publications (1)

Publication Number Publication Date
SG11201809387QA true SG11201809387QA (en) 2018-11-29

Family

ID=60203504

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201809387QA SG11201809387QA (en) 2016-05-02 2017-05-01 Compositions and methods related to hiv-1 immunogens

Country Status (13)

Country Link
US (4) US10647748B2 (en)
EP (1) EP3452494A4 (en)
JP (1) JP7046832B2 (en)
CN (1) CN109153704A (en)
AU (2) AU2017259275C1 (en)
BR (1) BR112018072248A2 (en)
CA (1) CA3022826A1 (en)
EA (1) EA201892233A1 (en)
IL (2) IL299962A (en)
MX (1) MX2018013455A (en)
SG (1) SG11201809387QA (en)
WO (1) WO2017192434A1 (en)
ZA (1) ZA201807216B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202092808A1 (en) * 2018-06-13 2021-08-24 Зе Скриппс Рисёрч Инститьют VACCINES BASED ON NANOPARTICLES WITH NEW STRUCTURAL COMPONENTS
US20220041650A1 (en) * 2018-12-03 2022-02-10 Duke University Purification method for recombinant proteins and nanoparticles
AU2020323462A1 (en) * 2019-07-26 2022-03-10 The Scripps Research Institute Engineered HCV E2 immunogens and related vaccine compositions
KR20220092896A (en) 2019-11-07 2022-07-04 얀센 백신스 앤드 프리벤션 비.브이. protein purification
CN111647078B (en) * 2020-06-22 2022-04-26 中国医学科学院医学生物学研究所 anti-HIV monoclonal antibody and preparation method and application thereof
US10906944B2 (en) 2020-06-29 2021-02-02 The Scripps Research Institute Stabilized coronavirus spike (S) protein immunogens and related vaccines
US20240000919A1 (en) * 2020-11-12 2024-01-04 Xiamen University Modified envelope protein of human immunodeficiency virus and use thereof
CN116769053B (en) * 2023-05-26 2023-12-15 华中农业大学 Recombinant AaLS-BPP fusion peptide, preparation method and application

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0735893T3 (en) 1993-09-14 2009-03-09 Pharmexa Inc PAN DR-binding peptides to enhance the immune response
US7550143B2 (en) 2005-04-06 2009-06-23 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
WO2008063331A2 (en) 2006-10-23 2008-05-29 Progenics Pharmaceuticals, Inc. Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof
CA2705373A1 (en) 2007-11-12 2009-08-20 The Henry M. Jackson Foundation For The Advancement Of Military Medicine , Inc. Hiv-1 envelope glycoprotein oligomer and methods of use
CA2713879C (en) 2008-02-01 2020-01-07 Alpha-O Peptides Ag Self-assembling peptide nanoparticles useful as vaccines
US9738688B2 (en) 2012-11-05 2017-08-22 International Aids Vaccine Initiative HIV-1 envelope glycoprotein
AP2015008634A0 (en) 2013-01-07 2015-07-31 Beth Israel Hospital Stabilized human immunodeficiency virus 'hiv' env elope 'env' trimer vaccines and methods of using same
US10400015B2 (en) 2014-09-04 2019-09-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant HIV-1 envelope proteins and their use
US10501733B2 (en) 2015-02-27 2019-12-10 University Of Washington Polypeptide assemblies and methods for the production thereof
IL294832A (en) * 2016-09-15 2022-09-01 Janssen Vaccines Prevention B V Trimer stabilizing hiv envelope protein mutations

Also Published As

Publication number Publication date
US20190048043A1 (en) 2019-02-14
US20220098244A1 (en) 2022-03-31
AU2021221582B2 (en) 2022-10-20
CN109153704A (en) 2019-01-04
ZA201807216B (en) 2020-01-29
MX2018013455A (en) 2019-02-28
AU2017259275B2 (en) 2021-06-24
JP7046832B2 (en) 2022-04-04
JP2019522626A (en) 2019-08-15
WO2017192434A1 (en) 2017-11-09
US20240083954A1 (en) 2024-03-14
AU2017259275C1 (en) 2022-01-27
EP3452494A4 (en) 2020-01-01
IL299962A (en) 2023-03-01
US11236134B2 (en) 2022-02-01
IL262582B2 (en) 2023-06-01
BR112018072248A2 (en) 2019-02-12
US10647748B2 (en) 2020-05-12
EP3452494A1 (en) 2019-03-13
AU2021221582A1 (en) 2021-10-07
EA201892233A1 (en) 2019-07-31
US20200165303A1 (en) 2020-05-28
AU2017259275A1 (en) 2018-11-15
IL262582A (en) 2018-12-31
US11767347B2 (en) 2023-09-26
CA3022826A1 (en) 2017-11-09

Similar Documents

Publication Publication Date Title
SG11201809387QA (en) Compositions and methods related to hiv-1 immunogens
SG11201903674YA (en) Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
SG11201901445TA (en) A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201810605UA (en) Selectively altering microbiota for immune modulation
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201807912SA (en) Vaccine against rsv
SG11201804411TA (en) Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
SG11201909572QA (en) Methods for the treatment of subjects having a hepatitis b virus (hbv) infection
SG11201808750PA (en) T cell receptors
SG11201901700UA (en) Biaryl compounds useful as immunomodulators
SG11201805229YA (en) Means and methods for treating hbv
SG11201806322QA (en) Maytansinoid derivatives, conjugates thereof, and methods of use
SG11201804836RA (en) Treatment of fibrosis
SG11201901790YA (en) Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof
SG11201811363YA (en) Anti-zika virus antibodies and methods of use
SG11201809594WA (en) Nicotine particles and compositions
SG11201810951RA (en) Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy
SG11201806018YA (en) Protein cage-stabilized pickering emulsions and the use thereof
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201907776WA (en) Replication lag-constrained deletion of data in a large-scale distributed data storage system
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201909561RA (en) Octree-based convolutional neural network
SG11201908075UA (en) A microneedle device
SG11201903042VA (en) Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome